Calamos Advisors’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$13.4M Buy
166,828
+3,763
+2% +$310K 0.05% 348
2025
Q4
$13.9M Sell
163,065
-6,593
-4% -$541K 0.05% 332
2025
Q3
$13.2M Hold
169,658
0.05% 355
2025
Q2
$13.3M Hold
169,658
0.05% 350
2025
Q1
$12.3M Buy
169,658
+1,708
+1% +$122K 0.05% 346
2024
Q4
$12.4M Buy
167,950
+228
+0.1% +$16K 0.05% 354
2024
Q3
$11.1M Sell
167,722
-4,099
-2% -$298K 0.05% 382
2024
Q2
$15.9M Sell
171,821
-6,289
-4% -$557K 0.07% 297
2024
Q1
$17M Sell
178,110
-4,463
-2% -$375K 0.08% 284
2023
Q4
$13.9M Sell
182,573
-3,080
-2% -$214K 0.07% 316
2023
Q3
$12.9M Hold
185,653
0.07% 330
2023
Q2
$17.5M Sell
185,653
-17
-0% -$1.48K 0.09% 284
2023
Q1
$15.4M Sell
185,670
-29,523
-14% -$2.32M 0.08% 325
2022
Q4
$16.1M Sell
215,193
-109,015
-34% -$8.4M 0.08% 305
2022
Q3
$26.8M Buy
324,208
+38
+0% +$3.66K 0.12% 200
2022
Q2
$30.8M Sell
324,170
-15,520
-5% -$1.61M 0.13% 184
2022
Q1
$40M Buy
339,690
+31,015
+10% +$3.48M 0.15% 161
2021
Q4
$40M Sell
308,675
-8,668
-3% -$1.01M 0.15% 158
2021
Q3
$35.9M Buy
317,343
+26,383
+9% +$3.01M 0.16% 167
2021
Q2
$30.1M Buy
290,960
+26,451
+10% +$2.49M 0.14% 190
2021
Q1
$22.1M Sell
264,509
-28,458
-10% -$2.41M 0.12% 192
2020
Q4
$26.7M Buy
292,967
+116,598
+66% +$9.67M 0.16% 171
2020
Q3
$14.1M Sell
176,369
-8,141
-4% -$635K 0.09% 241
2020
Q2
$12.8M Sell
184,510
-6,221
-3% -$442K 0.09% 248
2020
Q1
$12M Sell
190,731
-84,291
-31% -$6.08M 0.09% 241
2019
Q4
$21.4M Sell
275,022
-100,440
-27% -$7.84M 0.11% 229
2019
Q3
$27.5M Sell
375,462
-388,437
-51% -$27.3M 0.15% 190
2019
Q2
$47M Buy
763,899
+87,264
+13% +$5.28M 0.26% 112
2019
Q1
$43.2M Sell
676,635
-1,293
-0.2% -$73.8K 0.27% 112
2018
Q4
$34.6M Buy
677,928
+259,842
+62% +$13.1M 0.23% 122
2018
Q3
$24.3M Buy
418,086
+86,967
+26% +$4.25M 0.13% 198
2018
Q2
$16.1M Buy
331,119
+49,386
+18% +$2.31M 0.1% 255
2018
Q1
$13.1M Buy
281,733
+162,117
+136% +$7.04M 0.09% 277
2017
Q4
$4.49M Sell
119,616
-5,865
-5% -$215K 0.02% 409
2017
Q3
$4.57M Buy
125,481
+3,996
+3% +$152K 0.04% 378
2017
Q2
$4.79M Buy
121,485
+6,927
+6% +$253K 0.04% 386
2017
Q1
$3.59M Sell
114,558
-680,343
-86% -$21.3M 0.03% 403
2016
Q4
$24.8M Sell
794,901
-342,867
-30% -$11.1M 0.2% 150
2016
Q3
$45.7M Buy
1,137,768
+1,052,298
+1,231% +$39.6M 0.33% 89
2016
Q2
$2.84M Sell
85,470
-56,238
-40% -$1.92M 0.02% 410
2016
Q1
$4.17M Buy
141,708
+8,838
+7% +$244K 0.03% 357
2015
Q4
$3.5M Hold
132,870
0.02% 385
2015
Q3
$3.15M Buy
132,870
+48
+0% +$1.16K 0.02% 407
2015
Q2
$3.15M Sell
132,822
-7,482
-5% -$169K 0.02% 426
2015
Q1
$3.33M Buy
140,304
+64,914
+86% +$1.46M 0.02% 431
2014
Q4
$1.6M Buy
75,390
+390
+0.5% +$7.83K 0.01% 505
2014
Q3
$1.28M Hold
75,000
0.01% 495
2014
Q2
$1.07M Hold
75,000
0.01% 517
2014
Q1
$927K Hold
75,000
0.01% 515
2013
Q4
$822K Hold
75,000
0.01% 524
2013
Q3
$870K Hold
75,000
0.01% 487
2013
Q2
$840K Buy
+75,000
New +$888K 0.01% 472

Other funds holding EW

Calamos Advisors's EW Position: Q1 2026 in Review

Calamos Advisors increased its Edwards Lifesciences (EW) stake by 2.3% in Q1 2026, buying an estimated $310K and bringing the position to 166,828 shares worth $13.4M. The position accounts for 0.05% of the portfolio, ranked #348.

Calamos Advisors first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $47M in Q2 2019. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Calamos Advisors held 166,828 shares of Edwards Lifesciences worth $13.4M as of Q1 2026.
  • Calamos Advisors bought 3,763 Edwards Lifesciences shares in Q1 2026, an estimated $310K.
  • Edwards Lifesciences made up 0.05% of Calamos Advisors's portfolio in Q1 2026, its #348 holding.
  • Calamos Advisors first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
  • Calamos Advisors's Edwards Lifesciences position peaked at $47M in Q2 2019.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.